RAPT Therapeutics, Inc.

Equities

RAPT

US75382E1091

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 08/06/2024 am IST			5-day change	1st Jan Change
3.84 ^USD	-4.71%		-4.24%	-84.55%

14/05	Wolfe Research Downgrades RAPT Therapeutics to Peer Perform From Outperform	MT
10/05	Guggenheim Downgrades RAPT Therapeutics to Neutral From Buy	MT

Rapt Therapeutics, Inc. Announces Resignation of Peter Svennilson from Board of Directors

July 02, 2021 at 02:01 am IST

On June 30, 2021, Peter Svennilson notified RAPT Therapeutics, Inc. (the Company) of his decision to resign from the board of directors of the Company, effective as of June 30, 2021. Mr. Svennilson's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

Latest news about RAPT Therapeutics, Inc.

Wolfe Research Downgrades RAPT Therapeutics to Peer Perform From Outperform	14/05	MT
Guggenheim Downgrades RAPT Therapeutics to Neutral From Buy	10/05	MT
Barclays Downgrades RAPT Therapeutics to Equalweight, Price Target at $4	10/05	MT
US Equity Markets Close Higher Thursday as Jobless Claims Climb	10/05	MT
Sector Update: Health Care Stocks Higher Late Afternoon	10/05	MT
Sector Update: Health Care	10/05	MT
RAPT Therapeutics Shares Plunge After Wider Q1 Loss, Closing of Zelnecirnon Trials	10/05	MT
RAPT Therapeutics Shares Hit 52-Week Low After Trials Closed	09/05	DJ
RAPT Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients	09/04	CI
JPMorgan Lowers RAPT Therapeutics' Price Target to $13 From $15, Keeps Neutral Rating	27/03	MT
RAPT Therapeutics, Inc.(NasdaqGM:RAPT) dropped from S&P Biotechnology Select Industry Index	18/03	CI
RAPT Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03	CI
North American Morning Briefing : S&P 500 Futures -2-	23/02	DJ
RAPT Therapeutics Shares Decline Following UBS Downgrade	23/02	MT
UBS Downgrades RAPT Therapeutics to Neutral From Buy, Adjusts Price Target to $10 From $61	22/02	MT
North American Morning Briefing : Nvidia Ignites -2-	22/02	DJ
Barclays Adjusts Price Target on RAPT Therapeutics to $13 From $35, Maintains Overweight Rating	21/02	MT
Leerink Partners Downgrades RAPT Therapeutics to Market Perform From Outperform, Price Target is $10	21/02	MT
HC Wainwright Downgrades RAPT Therapeutics to Neutral From Buy	21/02	MT
JPMorgan Downgrades RAPT Therapeutics to Neutral From Overweight, Price Target is $15	21/02	MT
North American Morning Briefing : Stock Futures -2-	21/02	DJ
Sector Update: Health Care Stocks Lower Late Afternoon	21/02	MT
Top Midday Decliners	21/02	MT
Stifel Cuts RAPT Therapeutics' Price Target to $33 From $40, Keeps Buy Rating	20/02	MT

Chart RAPT Therapeutics, Inc.

Duration

Period

More charts

Company Profile

RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its drug discovery and development engine, it develops selective small molecules designed to modulate the critical immune responses underlying these diseases. Its lead inflammation drug candidate, zelnecirnon (RPT193), and its lead oncology drug candidate, tivumecirnon (FLX475), each target C-C motif chemokine receptor 4 (CCR4), a drug target that potentially has broad applicability in inflammatory diseases and oncology. Its inflammation drug candidate, zelnecirnon, is designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its oncology drug candidate, tivumecirnon, is designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors.

Sector

Biotechnology & Medical Research

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

4.03 USD

Average target price

14.83 USD

Spread / Average Target

+268.07%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
RAPT THERAPEUTICS, INC.	-84.55%	14Cr
VERTEX PHARMACEUTICALS INCORPORATED	+18.72%	13TCr
REGENERON PHARMACEUTICALS, INC.	+14.19%	11TCr
BIONTECH SE	-4.93%	2.46TCr
ARGENX SE	+3.23%	2.28TCr
GENMAB A/S	-10.44%	1.82TCr
WUXI APPTEC CO., LTD.	-41.74%	1.65TCr
BEIGENE, LTD.	-13.31%	1.65TCr
NEUROCRINE BIOSCIENCES, INC.	+2.44%	1.34TCr
SAREPTA THERAPEUTICS, INC.	+27.89%	1.11TCr

Bio Therapeutic Drugs